Search clinical trials for: XZP-3621

Total 249 results

Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC

ALK-positive NSCLC

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

Food Effect and Mass Balance Study of XZP-3621 Tablets

Healthy

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

ROS1 Rearrangement Non-small Cell Lung Cancer | ALK Rearrangement Non-small Cell Lung Cancer

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of the Absorption, Metabolism and Excretion of [14C]XZP-3621 in Human

Healthy Volunteers

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib

Non-small Cell Lung Cancer

China
Amolyt Pharma

Recruiting

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism (CALYPSO)

Endocrine System Diseases | Parathyroid Diseases | Chronic Hypoparathyroidism

Germany, United States, Spain, Italy, Denmark, United Kingdom, Hungary, France, Netherlands, Canada, Portugal, Poland
Amolyt Pharma

Completed

AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism

Chronic Hypoparathyroidism

Hungary, Netherlands
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

Effect of Food on the Pharmacokinetics of XZP-3287 in Healthy Subjects

Healthy

China
Sihuan Pharmaceutical Holdings Group Ltd.

Unknown

A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

Advanced Breast Cancer | Metastasis Solid Tumors

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

Drug-drug Interaction Study of XZP-3621 Tablet

Healthy Subjects

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects

Nonalcoholic Steatohepatitis (NASH)

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Clinical Trial of XZP-6019 Tablets in Healthy Subjects

Non-alcoholic Fatty Liver Disease

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Clinical Trial of XZP-3287 for Material Balance

Healthy Male Subjects

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Non-small Cell Lung Cancer

China
Tolerion, Inc.

Active, not recruiting

Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients (SUNRISE)

Diabetes Mellitus, Type 1

United States
European Organisation for Research and Treatment...

Completed

ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma

Lung Cancer | Melanoma (Skin)

France, Netherlands, Norway, Belgium, Switzerland, United Kingdom, Germany, Denmark, Austria
Tolerion, Inc.

Withdrawn

Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN) (DAWN)

Diabetes Mellitus, Type 1

United States
Tolerion, Inc.

Withdrawn

Diabetes AutoimmunitY Withdrawn in Established Patients (DAY) (DAY)

Diabetes Mellitus, Type 1
Mitsubishi Tanabe Pharma America Inc.

Completed

Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

Spinal Cord Injury

United States
Rubius Therapeutics

Terminated

RTX-321 Monotherapy in Patients With HPV 16+ Tumors

Cervical Cancer | Head and Neck Cancer | Anal Cancer

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

United States
Sihuan Pharmaceutical Holdings Group Ltd.

Terminated

XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes

Recurrent Genital Herpes
ALK-Abelló A/S

Completed

Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)

Allergy | Rhinitis | Conjunctivitis | Rhinoconjunctivitis
GRI Bio, Inc.

Terminated

Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease (GRI-201)

Chronic Liver Disease

South Africa
Parion Sciences

Terminated

Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Parion Sciences

Completed

Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
United BioPharma
Taipei Veterans General Hospital, Taiwan

Completed

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers

Herpes Simplex Virus Infection

Taiwan
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies

Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating MAC-321 in Colorectal Cancer

Colorectal Neoplasms | Rectal Neoplasms | Colonic Neoplasms
Elevation Oncology

Recruiting

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Neoplasms | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasm | Pancreas Neoplasm | Stomach Neoplasm

United States, Japan
Tranzyme, Inc.

Completed

Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Gastroparesis

United States, Belgium, Denmark, Finland, Germany, Norway, Poland, Sweden
Neuronascent, Inc.
National Institute on Aging (NIA)

Completed

Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers

Alzheimer Disease

United States
Parion Sciences

Terminated

Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Merck Sharp & Dohme LLC

Terminated

Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)

Advanced Solid Tumors

Germany, Spain, United Kingdom
ALK-Abelló A/S

Completed

A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)

Allergy
University of Aarhus
Medtronic

Completed

Subsensory Sacral Nerve Stimulation for Irritable Bowel Syndrome

Irritable Bowel Syndrome

Denmark
Pfizer

Terminated

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Solid Tumor | Hematologic Malignancies

United States, Canada
Jazz Pharmaceuticals

Completed

"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"

Obstructive Sleep Apnea | Narcolepsy

United States, France, Canada, Germany, Netherlands, Finland
Norgine

Completed

A Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101

Postoperative Ileus

United Kingdom
Medibiofarma S.L.

Recruiting

First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors

Cancer

Spain
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals

Recurrent Genital Herpes
University of Aarhus
Medtronic

Completed

Multimodal Stimulation Before and After Sacral Nerve Stimulation for Irritable Bowel Syndrome

Irritable Bowel Syndrome

Denmark
University of Aarhus

Completed

Long-term Sacral Nerve Stimulation for Irritable Bowel Syndrome.

Irritable Bowel Syndrome

Denmark
Advanz Pharma

Completed

A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)

Atrial Fibrillation
Jazz Pharmaceuticals
Children's Oncology Group (COG)

Completed

An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

Acute Lymphoblastic Leukemia | Lymphoblastic Leukemia

United States, Canada
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)

HTLV-1-Associated Myelopathy (HAM)

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males

Healthy Adult Males

Japan
X4 Pharmaceuticals

Active, not recruiting

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Neutropenia

United States
Tranzyme, Inc.

Completed

Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus

Diabetes Mellitus | Gastroparesis

United States, Denmark, Norway, Sweden, United Kingdom, Poland

Search clinical trials for: XZP-3621

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations